Enzastaurin (DB06486): A Comprehensive Pharmacological and Clinical Review of a Revitalized Kinase Inhibitor

1.0 Executive Summary

Enzastaurin is an orally available, investigational small-molecule drug, chemically classified as a synthetic bisindolylmaleimide, that functions as a serine/threonine kinase inhibitor. Originally developed by Eli Lilly and Company, its primary mechanism of action involves the potent and selective inhibition of Protein Kinase C beta (PKCβ), with secondary activity suppressing the critical PI3K/AKT cell survival pathway. This dual inhibition results in multifaceted antitumor effects, including the induction of apoptosis, suppression of cellular proliferation, and inhibition of tumor-induced angiogenesis.

The clinical development of Enzastaurin has followed a remarkable and instructive trajectory. Despite promising preclinical data, the drug's initial path was marked by a significant setback in 2013 with the failure of the pivotal Phase III PRELUDE trial, which found no benefit for Enzastaurin as a maintenance therapy in high-risk diffuse large B-cell lymphoma (DLBCL). This outcome led to the cessation of its development by the originator.

The program was revitalized when Denovo Biopharma acquired the global rights and applied a precision medicine strategy. Through retrospective genomic analysis of samples from the PRELUDE and other trials, a novel predictive biomarker, Denovo Genomic Marker 1 (DGM1), was identified. This biomarker stratified a subpopulation of patients who demonstrated a significant survival benefit from Enzastaurin treatment. This discovery prompted a second wave of development, culminating in two new biomarker-guided, global Phase III trials: the ENGINE study in first-line high-risk DLBCL and the ENGAGE study in newly diagnosed glioblastoma (GBM).

Concurrently, a strong, mechanistically distinct rationale emerged for repurposing Enzastaurin for the treatment of Vascular Ehlers-Danlos Syndrome (vEDS), a rare and life-threatening genetic disorder. Preclinical models demonstrated that Enzastaurin could correct the underlying PKC-driven pathology responsible for fatal vascular ruptures in vEDS. This led to the initiation of the pivotal Phase III PREVEnt trial by Aytu BioPharma.

However, the development path has encountered further significant hurdles. The PREVEnt trial for vEDS was suspended indefinitely due to financial constraints. Furthermore, the recent voluntary withdrawal of the FDA and EMA orphan drug designations for both GBM and DLBCL, occurring after the completion of the ENGAGE and ENGINE trials, strongly suggests that these studies failed to meet their primary endpoints.

At the recommended oral dose of 500 mg daily, Enzastaurin has a generally manageable safety profile, with common adverse events including fatigue and chromaturia. Dose-limiting toxicities, notably thrombocytopenia and QTc interval prolongation, have been observed at higher or more frequent doses. Its pharmacokinetic profile is complex, characterized by saturable absorption and a profound susceptibility to drug-drug interactions involving the CYP3A4 enzyme system.

Enzastaurin stands as a quintessential case study in modern pharmaceutical development. Its history illustrates the immense challenges of translating preclinical promise into clinical success, the transformative potential of biomarker-driven drug rescue, and the formidable scientific and financial barriers to bringing novel therapies to market for both oncologic and rare disease indications. While its future in oncology appears uncertain, the compelling scientific rationale for its use in vEDS remains an unresolved opportunity.

2.0 Introduction: A Profile of Enzastaurin

Enzastaurin (LY-317615) is a synthetic, acyclic bisindolylmaleimide developed as an orally administered, targeted antineoplastic agent.[1] Its creation by Eli Lilly and Company emerged from a strategic shift in cancer drug discovery during the 1990s, moving away from broad cytotoxic agents toward compounds designed to inhibit specific molecular pathways driving tumorigenesis.[3] Enzastaurin was engineered for the treatment of a wide spectrum of solid and hematological malignancies, predicated on its ability to modulate key cellular signaling cascades.[4]

The core pharmacological premise for Enzastaurin's development was its function as a potent and selective adenosine triphosphate (ATP)-competitive inhibitor of Protein Kinase C beta (PKCβ).[5] PKCβ is a member of the serine/threonine kinase family that serves as a critical node in signal transduction pathways regulating cellular proliferation, apoptosis, differentiation, and angiogenesis.[7] Dysregulation and overexpression of PKC isoforms, particularly PKCβ, have been implicated in the pathology of numerous cancers, including diffuse large B-cell lymphoma (DLBCL) and glioblastoma, where its expression is linked to poor prognosis.[7] By selectively targeting this enzyme, Enzastaurin was designed to disrupt tumor-induced angiogenesis and directly inhibit tumor cell growth and survival, offering a novel therapeutic strategy for these difficult-to-treat diseases.[9]

3.0 Physicochemical Characteristics and Formulation

Enzastaurin is a small molecule drug belonging to the chemical classes of indoles and maleimides.[11] Its definitive chemical structure is identified by the International Union of Pure and Applied Chemistry (IUPAC) name 3-(1-methylindol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione.[1]

The drug has been developed for oral administration and has been studied in both capsule and tablet formulations.[2] Much of the clinical research has utilized the hydrochloride salt form, Enzastaurin Hydrochloride (CAS Number: 359017-79-1), which possesses a distinct molecular formula (

C32​H30​ClN5​O2​) and molecular weight from the parent compound.[14] Enzastaurin itself is soluble in dimethyl sulfoxide (DMSO) but has very low predicted aqueous solubility, a property that influences its absorption characteristics.[16] Its computed properties, including a high partition coefficient (AlogP: 4.93) and a molecular weight exceeding 500 g/mol, result in one violation of Lipinski's Rule of Five, suggesting potential challenges with oral bioavailability and membrane permeability.[16] A comprehensive summary of its key identifiers and properties is provided in Table 1.

Table 1: Key Identifiers and Physicochemical Properties of Enzastaurin

Property	Value / Identifier	Source(s)
Drug Name	Enzastaurin	17
Synonyms	LY-317615, LY317615, enzastaurina	12
DrugBank ID	DB06486	12
CAS Number	170364-57-5	1
PubChem CID	176167	1
ChEMBL ID	CHEMBL300138	12
IUPAC Name	3-(1-methylindol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione	12
Molecular Formula	C32​H29​N5​O2​	11
Molecular Weight	515.617 g/mol	1
Solubility	Soluble in DMSO; Predicted Water Solubility: 0.00903 mg/mL	16
AlogP	4.93	18
Polar Surface Area	72.16 A˚2	18
H-Bond Donors (Lipinski)	1	18
H-Bond Acceptors (Lipinski)	7	18
Rule of Five Violations	1 (Molecular Weight > 500)	18

4.0 Nonclinical Pharmacology

The pharmacological activity of Enzastaurin is characterized by its dual inhibitory effect on two central signaling pathways that are frequently dysregulated in cancer, leading to a triad of antitumor cellular effects.

4.1 Primary Mechanism: Inhibition of Protein Kinase C Beta (PKCβ)

Enzastaurin functions as a potent and highly selective inhibitor of the beta isoform of Protein Kinase C (PKCβ).[5] It acts as an ATP-competitive inhibitor, binding to the ATP-binding site of the enzyme to block its kinase activity and prevent the phosphorylation of downstream substrates.[1] In vitro assays have established its potency, with an inhibitory concentration (

IC50​) of approximately 6 nM for PKCβ.[20] This inhibition is highly selective; Enzastaurin is 6- to 20-fold more selective for PKCβ compared to other PKC isoforms such as PKCα, PKCγ, and PKCε, which minimizes certain off-target effects associated with less specific PKC inhibitors.[20]

4.2 Secondary Mechanisms: Suppression of the PI3K/AKT Signaling Pathway

In addition to its primary target, Enzastaurin exerts a significant inhibitory effect on the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway.[7] This pathway is a master regulator of cell survival, proliferation, and metabolism, and its constitutive activation is a hallmark of many human cancers.[8] The ability of Enzastaurin to modulate two of the most critical oncogenic signaling networks simultaneously provides a more comprehensive blockade of tumor growth signals than would be achieved by targeting either pathway alone. This dual action may circumvent potential resistance mechanisms where one pathway compensates for the inhibition of the other.

4.3 Downstream Cellular Effects: Anti-proliferative, Pro-apoptotic, and Anti-angiogenic Activity

The dual inhibition of the PKCβ and PI3K/AKT pathways by Enzastaurin translates into three primary downstream antitumor effects:

1. Anti-angiogenesis: PKCβ is a crucial mediator of the signaling cascade initiated by vascular endothelial growth factor (VEGF), the most potent driver of angiogenesis.[2] By inhibiting PKCβ, Enzastaurin effectively blocks VEGF-stimulated neo-angiogenesis, thereby restricting the formation of new blood vessels required to supply tumors with oxygen and nutrients.[1] Preclinical studies have validated this effect, showing that Enzastaurin suppresses neovasculature in the rat corneal micropocket assay and reduces microvessel density in human tumor xenografts.[2]
2. Induction of Apoptosis: By suppressing the pro-survival signals emanating from the PI3K/AKT pathway, Enzastaurin promotes programmed cell death, or apoptosis, in cancer cells.[6] This has been demonstrated across a diverse panel of cancer cell lines derived from glioblastoma, lymphoma, multiple myeloma, and colon cancer.[7]
3. Inhibition of Proliferation: The combined blockade of PKCβ and PI3K/AKT signaling interrupts the pathways that drive uncontrolled cell division, leading to a potent anti-proliferative effect.[7]

The molecular consequence of this pathway inhibition is a measurable reduction in the phosphorylation of key downstream effector proteins, most notably Glycogen Synthase Kinase-3 beta (GSK3β) and the ribosomal protein S6.[7] The level of phosphorylated GSK3β, in particular, has been identified as a useful pharmacodynamic biomarker to confirm the biological activity of Enzastaurin in both preclinical models and clinical samples.[7]

4.4 Preclinical Efficacy in Oncology and vEDS Models

Enzastaurin demonstrated substantial antitumor activity in numerous preclinical cancer models. In vivo studies using human tumor xenografts showed that oral administration of Enzastaurin led to significant tumor growth delay in models of glioblastoma (U87MG), colorectal cancer (HCT116), and non-small cell lung cancer (NSCLC).[7] Furthermore, it exhibited additive or even synergistic antitumor effects when combined with standard-of-care cytotoxic agents, such as pemetrexed in NSCLC models, providing a strong rationale for its clinical investigation in combination regimens.[7]

The scientific basis for repurposing Enzastaurin for Vascular Ehlers-Danlos Syndrome (vEDS) is mechanistically distinct and compelling. Research led by Dr. Hal Dietz utilized a genetically engineered knock-in mouse model that accurately recapitulates the human disease, which is caused by mutations in the COL3A1 gene.[25] Transcriptional profiling of aortic tissue from these mice revealed that excessive PKC/ERK pathway signaling was a primary molecular driver of the vascular pathology, leading to fatal aortic rupture.[25] Subsequent experiments demonstrated that treatment with Enzastaurin, a potent PKCβ inhibitor, was highly efficacious in this model, significantly reducing the risk of death from vascular dissection and preventing the lethal phenotype.[25] This provides a direct, cause-and-effect therapeutic hypothesis, where Enzastaurin is not just targeting a general cancer pathway but is correcting a specific, disease-driving molecular defect.

5.0 Clinical Pharmacology: Pharmacokinetics and Pharmacodynamics

The clinical pharmacology of Enzastaurin is complex and presents several challenges that have profoundly influenced its clinical development and interpretation of trial results. Its pharmacokinetic profile is characterized by saturable absorption, high protein binding, extensive metabolism with active metabolites, and a critical susceptibility to drug-drug interactions.

5.1 Absorption, Distribution, Metabolism, and Excretion (ADME)

• Absorption: Enzastaurin is administered orally. However, its absorption from the gastrointestinal tract is saturable. Phase I dose-escalation studies demonstrated that plasma exposures of Enzastaurin and its metabolites reached a plateau at doses above 500-700 mg once daily.[13] This dose-limiting absorption meant that simply increasing the daily dose was ineffective at achieving higher systemic concentrations, a key factor that established 500 mg daily as the recommended dose for further development.[7]
• Distribution: Once absorbed, Enzastaurin is extensively bound to plasma proteins, with approximately 95% of the drug being bound.[2] This high degree of protein binding is a critical pharmacological feature, as only the small, unbound fraction (5%) is free to distribute into tissues and exert a therapeutic effect. Consequently, a high total plasma concentration is required to achieve a therapeutically effective free-drug concentration.
• Metabolism: The primary route of elimination for Enzastaurin is extensive hepatic metabolism mediated by the cytochrome P450 3A (CYP3A) enzyme subfamily, particularly CYP3A4.[2] This process generates multiple metabolites, at least three of which—LSN326020 (a desmethylenepyrimidyl metabolite), LY485912 (a desmethyl metabolite), and LSN2406799 (a hydroxymethyl intermediate)—are also pharmacologically active, inhibiting PKCβ with potencies similar to the parent compound.[2] The presence of these active metabolites, especially the primary metabolite LSN326020 with its significantly longer elimination half-life (42 hours) compared to the parent drug (14 hours), means that the overall pharmacological activity and potential for drug accumulation are driven by a composite of both the parent drug and its metabolites.[8]
• Excretion: Enzastaurin and its metabolites undergo minimal renal elimination, with the vast majority cleared via hepatic metabolism.[24]

5.2 Influence of Food and Dose-Limiting Absorption

The bioavailability of Enzastaurin is significantly affected by food. Administration with a high-fat meal has been shown to substantially increase systemic exposure to the drug and its metabolites.[13] To ensure maximal and consistent absorption, clinical trial protocols mandated that patients take Enzastaurin within 30-60 minutes of a meal.[2] The dose-limiting absorption observed above 500 mg daily presented a therapeutic ceiling that could not be easily overcome. An attempt to bypass this by splitting the total daily dose (e.g., 250 mg twice daily) did result in higher average drug concentrations but was associated with unacceptable toxicity, likely due to the accumulation of long-lived active metabolites.[13]

5.3 Critical Drug-Drug Interactions (CYP3A4 Inducers/Inhibitors, EIAEDs)

Enzastaurin's heavy reliance on CYP3A4 for its metabolism makes it highly vulnerable to clinically significant drug-drug interactions.

• CYP3A4 Inducers: Co-administration with potent inducers of CYP3A4 can drastically accelerate the metabolism of Enzastaurin, leading to sub-therapeutic plasma concentrations. This interaction is particularly problematic in the treatment of brain tumors like glioblastoma, where many patients are prescribed enzyme-inducing antiepileptic drugs (EIAEDs) such as carbamazepine, oxcarbazapine, and phenytoin to control seizures.[13] Clinical studies in this population revealed that patients taking EIAEDs had Enzastaurin serum exposure levels that were approximately 80% lower than those of patients not on these medications.[9] This profound interaction necessitated the stratification of patients into separate cohorts in clinical trials and likely contributed to a lack of efficacy in a significant portion of the glioma patient population who were effectively under-dosed.[9]
• CYP3A4 Inhibitors: Conversely, concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) is expected to impair Enzastaurin's metabolism, leading to elevated plasma concentrations and an increased risk of toxicity.[32] For this reason, clinical trial protocols typically excluded patients requiring treatment with strong CYP3A4 inhibitors or inducers.[32]

5.4 Pharmacodynamic Markers

Based on its in vitro potency and high plasma protein binding, the target mean steady-state total plasma concentration (parent drug plus active metabolites) for clinical efficacy was established at approximately 1,400 nmol/L.[9] This concentration was expected to yield a free-drug level sufficient to inhibit 90% of PKCβ activity (

IC90​).[28] To monitor the biological effect of the drug in patients, the phosphorylation of GSK3β in peripheral blood mononuclear cells was identified as a viable pharmacodynamic biomarker, providing evidence of target engagement and downstream inhibition of the PI3K/AKT pathway.[9]

Table 2: Summary of Key Pharmacokinetic Parameters

Parameter	Enzastaurin (Parent Drug)	LSN326020 (Primary Active Metabolite)	Source(s)
Elimination Half-life (t1/2​)	14 hours	42 hours	8
Time to Max Concentration (tmax,ss​)	4.0 hours	6.0 hours	8
Max Concentration (Cmax,ss​)	2370 nmol/L	1070 nmol/L	8
Average Concentration (Cav,ss​)	1210 nmol/L	907 nmol/L	8
Area Under the Curve (AUCτ,ss​)	29,100 nmol·h/L	21,800 nmol·h/L	8
Plasma Protein Binding	~95%	Not specified	2
Target Steady-State Concentration (Total Analytes)	\multicolumn{2}{c	}{≥ 1400 nmol/L}	9

6.0 Clinical Development and Efficacy

The clinical history of Enzastaurin is a compelling narrative of initial promise, significant failure, and a subsequent, innovative revival driven by precision medicine, followed by further setbacks. This journey spans multiple cancer types and a rare genetic disorder, offering profound lessons in drug development.

6.1 Phase I-II Trials Across Solid and Hematologic Malignancies

Initial Phase I dose-escalation studies in patients with advanced solid tumors successfully established a recommended Phase II dose of 525 mg once daily (later formulated as a 500 mg tablet).[7] These early trials highlighted the drug's favorable safety profile at this dose, with no significant Grade 3 or 4 toxicities, and defined the key pharmacokinetic characteristic of dose-saturating absorption, which rendered a maximum tolerated dose (MTD) determination moot.[2]

Subsequently, Enzastaurin was evaluated in numerous Phase II trials across a broad range of indications, including NSCLC, glioblastoma, mantle cell lymphoma, follicular lymphoma, and cutaneous T-cell lymphoma.[9] The results from these single-agent studies were generally modest. While the drug demonstrated some biological activity, evidenced by stable disease in a subset of patients and occasional partial responses in highly refractory settings—such as in patients with relapsed DLBCL and recurrent glioma—the overall efficacy was insufficient to support its advancement as a monotherapy in unselected patient populations.[9] One notable signal of activity was a partial response lasting over eight months in a patient with relapsed DLBCL.[8]

6.2 The PRELUDE Trial: A Pivotal Failure in Diffuse Large B-Cell Lymphoma

Based on the promising signals in lymphoma, Eli Lilly launched the PRELUDE trial (NCT00332202), a large-scale, multicenter, randomized, double-blind, placebo-controlled Phase III study.[37] The trial enrolled 758 patients with high-risk DLBCL (International Prognostic Index [IPI] score ≥ 3) who had achieved a complete response after standard first-line R-CHOP chemotherapy.[37] The objective was to determine if maintenance therapy with Enzastaurin (500 mg daily for up to three years) could prevent disease relapse and improve disease-free survival (DFS).[37]

In 2013, the trial was declared a failure.[1] After a median follow-up of 48 months, the results showed no statistically significant difference in the primary endpoint of DFS between the Enzastaurin and placebo groups. The hazard ratio for DFS was 0.92, and the 4-year DFS rates were nearly identical at 70% for Enzastaurin versus 71% for placebo.[30] This definitive negative result led Eli Lilly to halt further development of Enzastaurin for lymphoma and largely shelve the asset.[1]

6.3 The Rise of the DGM1 Biomarker: A Second Chance for Enzastaurin

The trajectory of Enzastaurin changed dramatically after Denovo Biopharma acquired the worldwide rights to the compound.[40] Denovo's strategy was to re-evaluate failed drugs by applying modern pharmacogenomic tools to identify biomarkers that could predict response in a subset of patients.[41] The company performed a retrospective, genome-wide analysis on archived DNA samples from patients who had participated in the PRELUDE trial.[30]

This analysis led to the discovery of a novel, proprietary genetic biomarker named Denovo Genomic Marker 1 (DGM1), a germline polymorphism.[30] The analysis revealed a striking correlation: DGM1-positive patients in the PRELUDE trial who received Enzastaurin had a significantly improved overall survival (OS) compared to DGM1-negative patients on the drug (Hazard Ratio 0.27; p=0.0002).[39]

To validate this finding, the DGM1 biomarker was tested in an independent dataset from the Phase II S028 trial, which had evaluated Enzastaurin in combination with R-CHOP in the first-line setting. The result was a powerful replication: high-risk, DGM1-positive patients treated with the Enzastaurin-R-CHOP combination showed a dramatic OS benefit compared to DGM1-positive patients receiving R-CHOP alone (HR 0.28; p=0.018).[43] Importantly, DGM1 status had no impact on survival in the placebo/control arms of these studies, indicating that it was a predictive biomarker for Enzastaurin efficacy, not merely a prognostic marker for the disease itself.[45]

6.4 The ENGINE and ENGAGE Trials: A New Paradigm in DLBCL and Glioblastoma

The compelling retrospective data for the DGM1 biomarker provided a strong rationale to resurrect Enzastaurin's clinical development, this time within a precision medicine framework. Denovo Biopharma launched two prospective, biomarker-guided Phase III trials to confirm the initial findings.

• ENGINE Trial (NCT03263026): This global, randomized, placebo-controlled study was designed to prospectively validate the DGM1 hypothesis in DLBCL.[43] It enrolled approximately 235 treatment-naïve patients with high-risk (IPI ≥ 3) DLBCL, who were randomized to receive standard R-CHOP plus Enzastaurin or R-CHOP plus placebo.[44] The primary endpoint was overall survival specifically within the DGM1-positive patient cohort.[43] The trial completed enrollment in November 2020 and was marked as completed in July 2022.[48] However, as of late 2024, detailed results have not been publicly released. The ClinicalTrials.gov record for the study indicates a planned results posting date in early 2025.[42]
• ENGAGE Trial (NCT03776071): Retrospective analysis also suggested that the DGM1 biomarker was predictive of response in patients with glioblastoma.[31] This led to the initiation of the ENGAGE trial, a randomized, double-blind, placebo-controlled Phase III study evaluating Enzastaurin added to the standard-of-care regimen of temozolomide and radiation therapy in newly diagnosed GBM patients.[31] The study was designed to assess the primary endpoint of overall survival in patients prospectively identified as DGM1-positive.[50] The trial was officially completed in February 2024, but as with the ENGINE trial, no results have been posted to date.[52]

6.5 The PREVEnt Trial: A Strategic Pivot to Vascular Ehlers-Danlos Syndrome

Leveraging the strong preclinical evidence of efficacy in a genetically faithful mouse model of vEDS, Aytu BioPharma initiated a program to repurpose Enzastaurin for this rare, life-threatening connective tissue disorder.[25]

• PREVEnt Trial (NCT05463679): Following clearance of an Investigational New Drug (IND) application from the FDA, Aytu launched the global Phase III PREVEnt trial in July 2022.[25] This was a randomized, double-blind, placebo-controlled study designed to evaluate whether Enzastaurin could prevent major arterial events in patients with a confirmed COL3A1 gene mutation.[56] The planned enrollment was approximately 260 patients.[58]
• Status: In a significant setback for the vEDS community, Aytu BioPharma announced in October 2022—just a few months after initiation—that it was indefinitely suspending the PREVEnt trial and all related clinical development.[56] The decision was not based on scientific or safety concerns but was a strategic financial move to conserve capital, with the company projecting savings of over $20 million in future study costs, and to focus on its commercial operations.[60]

7.0 Safety and Tolerability Profile

The safety of Enzastaurin has been evaluated in over 3,000 patients across numerous clinical trials for various oncologic indications.[39] At the standard therapeutic dose of 500 mg once daily, the drug has demonstrated a generally favorable and manageable safety profile, a characteristic that distinguished it from earlier, more toxic PKC inhibitors.[7]

7.1 Common and Notable Adverse Events

A pooled analysis of safety data from 135 patients treated in early-phase trials provides a representative overview of the most common toxicities.[62] Treatment-emergent adverse events (TEAEs) occurring in 15% or more of patients were primarily low-grade and included fatigue (31%), cough (19%), diarrhea (19%), nausea (19%), constipation (17%), and peripheral edema (17%).[62]

A distinctive and frequently reported drug-related event is chromaturia, a reddish-orange discoloration of the urine, observed in approximately 14-15% of patients.[8] This is a benign effect attributed to the inherent color of the active pharmaceutical ingredient and its metabolites and is not indicative of renal toxicity.[62]

7.2 Dose-Limiting Toxicities and Serious Adverse Events

While well-tolerated at the 500 mg daily dose, attempts to increase drug exposure through higher or more frequent dosing revealed significant dose-limiting toxicities (DLTs).[13] In a Phase I trial evaluating total daily doses of 500 mg, 800 mg, and 1,000 mg, Enzastaurin was found to be poorly tolerated, with the primary DLTs being hematologic and cardiac:

• Thrombocytopenia: A significant decrease in platelet count.
• Prolonged QTc Interval: An abnormality in the heart's electrical cycle that can increase the risk of serious arrhythmias.

This finding of QTc prolongation was consistent with preclinical toxicology studies in dogs, which also observed this effect at high drug exposures.[2] Other serious (Grade 3 or higher) adverse events reported in clinical trials, though less common, have included thromboembolic events (e.g., pulmonary embolism), hemorrhage, and elevated liver enzymes (alanine aminotransferase).[9] In a study involving patients with Waldenstrom's macroglobulinemia, one death from septic shock was considered possibly related to the drug.[21]

7.3 Special Populations and Contraindications

Formal prescribing information for Enzastaurin does not exist as it is an investigational agent. However, the exclusion criteria from its numerous clinical trials provide a clear picture of contraindications and populations requiring special caution.

• Contraindications: Patients with a personal or immediate family history of long QT syndrome or those with a baseline corrected QT (QTc) interval exceeding 450 msec for males or 470 msec for females were consistently excluded from trials.[32]
• Drug Interactions: Concomitant use of other medications known to prolong the QT interval was prohibited.[32] Similarly, due to the critical role of CYP3A4 in Enzastaurin's metabolism, patients requiring treatment with strong inducers (e.g., EIAEDs, rifampin) or strong inhibitors (e.g., ketoconazole) of CYP3A4 were excluded to avoid unpredictable and extreme alterations in drug exposure.[32]
• Other Exclusions: Standard exclusions for oncology trials were applied, including pregnancy, breastfeeding, and severe, uncontrolled comorbid conditions.[47]

Table 3: Summary of Treatment-Emergent Adverse Events (TEAEs) from a Pooled Analysis (N=135)

Adverse Event	All Events (All Grades, %)	Drug-Related Events (Grade 3/4, n)	Source(s)
Fatigue	31%	2	62
Cough	19%	0	62
Diarrhea	19%	0	62
Nausea	19%	0	62
Constipation	17%	0	62
Peripheral Edema	17%	0	62
Chromaturia	15%	0	62
Thrombocytopenia	Not specified in this analysis	DLT at higher doses	13
QTc Prolongation	Not specified in this analysis	DLT at higher doses	13
Thromboembolic Events	Not specified in this analysis	Reported as Grade ≥3	9

8.0 Regulatory History and Status

The regulatory journey of Enzastaurin with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) has been long and complex, reflecting its fluctuating development prospects. It has received multiple designations intended to facilitate the development of drugs for serious or rare diseases, but has also faced significant recent setbacks.

8.1 Orphan Drug Designations: Grants and Withdrawals

Orphan Drug Designation is granted to encourage the development of medicines for rare diseases (affecting fewer than 200,000 people in the U.S. or 5 in 10,000 in the E.U.) by providing incentives such as market exclusivity upon approval.[63] Enzastaurin has received several such designations, though its status has recently changed for its primary oncology indications.

• Glioblastoma (GBM) / Glioma:
• FDA: Granted Orphan Drug Designation for the treatment of glioblastoma multiforme on September 19, 2005. This designation was officially withdrawn or revoked on June 24, 2024.[65]
• EMA: Granted orphan designation for the treatment of glioma on December 23, 2005. This designation was withdrawn at the sponsor's request in May 2024.[66]
• Diffuse Large B-Cell Lymphoma (DLBCL):
• FDA: Granted Orphan Drug Designation on March 4, 2009. This designation was withdrawn or revoked on November 16, 2023.[68]
• EMA: Granted orphan drug designation on March 26, 2007. This designation is now listed as withdrawn/expired.[63]
• Ehlers-Danlos Syndrome (EDS):
• FDA: Granted Orphan Drug Designation for the treatment of Ehlers-Danlos Syndrome on December 7, 2021.[25]
• EMA: Granted orphan designation for the treatment of Ehlers-Danlos Syndrome on February 24, 2022.[58]

The voluntary withdrawal of the orphan designations for both GBM and DLBCL by the sponsor is a highly significant event. Such designations carry substantial financial incentives, including seven years of market exclusivity post-approval. A sponsor is highly unlikely to relinquish these benefits unless the path to regulatory approval for that indication is no longer considered viable. The timing of these withdrawals—occurring in late 2023 and mid-2024, after the completion of the pivotal ENGINE (DLBCL) and ENGAGE (GBM) trials, respectively—strongly implies that these biomarker-guided studies did not meet their primary endpoints.

8.2 Fast Track Designation and Investigational New Drug (IND) Applications

• Fast Track Designation (FDA): On July 17, 2020, the FDA granted Fast Track Designation to Enzastaurin for the treatment of newly diagnosed GBM patients positive for the DGM1 biomarker. This designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.[39]
• Investigational New Drug (IND) Application: The FDA cleared an IND application in December 2021, allowing Aytu BioPharma to proceed with the pivotal Phase III PREVEnt trial of Enzastaurin for the treatment of vEDS.[25]

Table 4: Timeline of Key Regulatory Milestones

Date	Regulatory Agency	Action	Indication	Source(s)
Sep 19, 2005	FDA	Orphan Drug Designation Granted	Glioblastoma Multiforme	65
Dec 23, 2005	EMA	Orphan Designation Granted	Glioma	66
Mar 26, 2007	EMA	Orphan Designation Granted	Diffuse Large B-Cell Lymphoma	63
Mar 04, 2009	FDA	Orphan Drug Designation Granted	Diffuse Large B-Cell Lymphoma	68
Jul 17, 2020	FDA	Fast Track Designation Granted	Newly Diagnosed Glioblastoma (DGM1+)	39
Dec 07, 2021	FDA	Orphan Drug Designation Granted	Ehlers-Danlos Syndrome	25
Dec 13, 2021	FDA	IND Application Cleared	Vascular Ehlers-Danlos Syndrome	25
Feb 24, 2022	EMA	Orphan Designation Granted	Ehlers-Danlos Syndrome	58
Nov 16, 2023	FDA	Orphan Drug Designation Withdrawn	Diffuse Large B-Cell Lymphoma	68
May 2024	EMA	Orphan Designation Withdrawn	Glioma	67
Jun 24, 2024	FDA	Orphan Drug Designation Withdrawn	Glioblastoma Multiforme	65

9.0 Expert Analysis and Future Directions

The development history of Enzastaurin offers a rich and multifaceted case study that encapsulates some of the most critical themes in modern pharmacology: the promise and peril of targeted therapies, the transformative power of precision medicine, and the stark economic realities of drug development for rare diseases. Its journey from a broadly targeted oncology agent to a biomarker-defined niche therapeutic and a repurposed candidate for a rare genetic disorder provides invaluable lessons for the biopharmaceutical industry.

9.1 Enzastaurin as a Case Study in Precision Medicine and Drug Repurposing

Enzastaurin's story is a powerful, real-world illustration of the "drug rescue" paradigm. After its definitive failure in the large, unselected PRELUDE trial, the drug was effectively abandoned. Its revival by Denovo Biopharma, based on a strategy of applying retrospective genomic screening to archived clinical trial samples, represents a triumph of the precision medicine concept. The identification of the DGM1 biomarker appeared to turn a failed trial into a success for a specific sub-population, providing a compelling rationale to reinvest in two new, costly Phase III trials.

However, the subsequent withdrawal of orphan drug designations for both DLBCL and GBM following the completion of these prospective trials serves as a crucial and sobering counterpoint. This sequence of events strongly suggests that the promising retrospective signal from DGM1 did not translate into a statistically significant clinical benefit when tested prospectively. This outcome highlights the immense challenge of validating retrospective biomarker findings. A single germline polymorphism, while correlated with an outcome, may not be sufficient to capture the complex biological heterogeneity of diseases like DLBCL and GBM or may not be robust enough to overcome other confounding factors in a prospective setting. This journey underscores that while biomarker-guided approaches are the future of oncology, the path from a promising retrospective signal to a validated predictive marker is fraught with scientific and statistical hurdles.

9.2 Challenges and Opportunities in Biomarker-Guided Trials

The pharmacokinetic profile of Enzastaurin was a significant confounding factor throughout its development. The combination of saturable absorption, high protein binding, and extreme sensitivity to metabolism by CYP3A4 inducers like EIAEDs created a "perfect storm" of pharmacokinetic challenges. It is highly probable that a substantial number of patients in early trials, particularly for glioblastoma, were significantly under-dosed, which could have masked a true drug effect and contributed to the initial negative results. The inability to overcome this with simple dose escalation due to absorption saturation established a therapeutic ceiling that may have been too low for a broad population but potentially sufficient for a hypersensitive DGM1-positive subgroup—a hypothesis that now appears to have been disproven. This experience emphasizes that a deep understanding of a drug's clinical pharmacology is a prerequisite for designing effective trials, especially when potent drug-drug interactions are at play.

9.3 The Unresolved Potential in vEDS and Other Indications

While the future of Enzastaurin in oncology appears bleak, its scientific rationale for treating Vascular Ehlers-Danlos Syndrome remains distinct and compelling. Unlike the more general "target an overexpressed kinase" approach in cancer, the vEDS hypothesis is based on correcting a specific, disease-driving molecular defect identified in a genetically faithful animal model. The suspension of the PREVEnt trial was a decision driven by financial strategy rather than scientific or safety concerns. This leaves a significant unmet medical need for vEDS patients and a scientifically plausible therapeutic candidate stranded in development limbo. The future of Enzastaurin in vEDS now depends entirely on whether a new sponsor or partner with sufficient capital can be found to resurrect and complete the pivotal trial. The situation starkly illustrates the vulnerability of rare disease drug development, where even programs with strong scientific merit can be derailed by economic pressures.

9.4 Concluding Remarks on the Future of Enzastaurin

Enzastaurin's legacy may ultimately be defined more by the lessons it has taught the field of drug development than by its clinical successes. It stands as a testament to both the potential of precision medicine to find value in failed assets and the immense difficulty of prospectively validating those findings. It highlights the absolute necessity of accounting for complex pharmacokinetics and drug interactions in clinical trial design. While its path to approval in oncology has likely closed, the compelling preclinical evidence in vEDS represents a significant piece of unfinished business. The ultimate fate of Enzastaurin now hinges on whether the vEDS program can be revived, offering a final opportunity for this well-traveled molecule to fulfill its therapeutic potential for a patient population with no approved treatments.

Works cited

1. Enzastaurin - Wikipedia, accessed August 19, 2025, https://en.wikipedia.org/wiki/Enzastaurin
2. Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer | Journal of Clinical Oncology - ASCO Publications, accessed August 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2005.05.3447
3. The evolution of cancer research and drug discovery at Lilly Research Laboratories - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/16143373/
4. Enzastaurin: A lesson in drug development - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/28325267/
5. en.wikipedia.org, accessed August 19, 2025, https://en.wikipedia.org/wiki/Enzastaurin#:~:text=Binding%20to%20the%20ATP%2Dbinding,tumor%20blood%20supply%2C%20preventing%20growth.
6. Enzastaurin: A Lesson in Drug Development - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/313624286_Enzastaurin_A_Lesson_in_Drug_Development
7. Enzastaurin, a Protein Kinase Cβ–Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer - AACR Journals, accessed August 19, 2025, https://aacrjournals.org/clincancerres/article/13/15/4641s/194304/Enzastaurin-a-Protein-Kinase-C-Selective-Inhibitor
8. A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma | Oncotarget, accessed August 19, 2025, https://www.oncotarget.com/article/7875/text/
9. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas - PMC, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2940576/
10. Enzastaurin - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/17906457/
11. pubchem.ncbi.nlm.nih.gov, accessed August 19, 2025, [https://pubchem.ncbi.nlm.nih.gov/compound/Enzastaurin#:~:text=3%2D(1%2Dmethyl%2D3,and%20a%20member%20of%20maleimides.](https://www.google.com/url?q=https://pubchem.ncbi.nlm.nih.gov/compound/Enzastaurin%23:~:text%3D3%252D(1%252Dmethyl%252D3,and%2520a%2520member%2520of%2520maleimides.&sa=D&source=editors&ust=1755605830143243&usg=AOvVaw0mtHy0Xg6eOV4MDea-Wsts)
12. Enzastaurin | C32H29N5O2 | CID 176167 - PubChem, accessed August 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Enzastaurin
13. A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas - AACR Journals, accessed August 19, 2025, https://aacrjournals.org/clincancerres/article/15/10/3617/73513/A-Phase-I-Trial-of-Enzastaurin-in-Patients-with
14. Enzastaurin Hydrochloride | C32H30ClN5O2 | CID 176166 - PubChem, accessed August 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/176166
15. Definition of enzastaurin hydrochloride - NCI Drug Dictionary, accessed August 19, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/enzastaurin-hydrochloride
16. Enzastaurin Hydrochloride | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/salts/DBSALT002020
17. CAS 170364-57-5 Enzastaurin - BOC Sciences, accessed August 19, 2025, https://www.bocsci.com/enzastaurin-cas-170364-57-5-item-84-85618.html
18. Compound: ENZASTAURIN (CHEMBL300138) - ChEMBL - EMBL-EBI, accessed August 19, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL300138
19. Enzastaurin - PharmaKB, accessed August 19, 2025, https://www.pharmakb.com/drug-report/enzastaurin
20. Enzastaurin (LY317615) | PKCβ Inhibitor - MedchemExpress.com, accessed August 19, 2025, https://www.medchemexpress.com/Enzastaurin.html
21. Enzastaurin – Knowledge and References - Taylor & Francis, accessed August 19, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Enzastaurin/
22. (PDF) A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/297639834_A_pharmacokinetic_and_safety_study_of_a_fixed_oral_dose_of_enzastaurin_HCl_in_native_Chinese_patients_with_refractory_solid_tumors_and_lymphoma/download
23. New Data Show Enzastaurin's Activity Across Multiple Cancer Cell Lines - Eli Lilly Investors, accessed August 19, 2025, https://investor.lilly.com/news-releases/news-release-details/new-data-show-enzastaurins-activity-across-multiple-cancer-cell
24. Pharmacokinetic interaction and safety of enzastaurin and pemetrexed in patients with advanced or metastatic cancer | Request PDF - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/339825120_Pharmacokinetic_interaction_and_safety_of_enzastaurin_and_pemetrexed_in_patients_with_advanced_or_metastatic_cancer
25. Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome - The VEDS Movement, accessed August 19, 2025, https://thevedsmovement.org/2021/12/15/aytu-biopharma-announces-fda-clearance-of-investigational-new-drug-ind-application-for-ar101-enzastaurin-in-vascular-ehlers-danlos-syndrome/
26. Clinical Trials - FIGHT vEDS, accessed August 19, 2025, https://www.fightveds.org/clinical-trials
27. Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer - AACR Journals, accessed August 19, 2025, https://aacrjournals.org/clincancerres/article/13/15/4474/194274/Phase-I-Pharmacokinetic-and-Pharmacodynamic-Study
28. Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11159132/
29. A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma - PMC - PubMed Central, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4951311/
30. Full article: ENGINE: A Phase III Randomized Placebo Controlled Study of Enzastaurin/R-CHOP as Frontline Therapy in High-Risk Diffuse Large B-Cell Lymphoma Patients with the Genomic Biomarker DGM1 - Taylor & Francis Online, accessed August 19, 2025, https://www.tandfonline.com/doi/full/10.2217/fon-2020-0176
31. New Phase 3 Trial of Targeted Therapy for Newly Diagnosed Glioblastoma, accessed August 19, 2025, https://braintumorcenter.ucsf.edu/news/new-phase-3-trial-targeted-therapy-newly-diagnosed-glioblastoma
32. A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 - Mayo Clinic, accessed August 19, 2025, https://www.mayo.edu/research/clinical-trials/cls-20521961
33. Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity - Mikus, accessed August 19, 2025, https://tcr.amegroups.org/article/view/16370/14025
34. Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma | ClinicalTrials.gov, accessed August 19, 2025, https://www.clinicaltrials.gov/study/NCT00088205
35. A Study of Enzastaurin in Participants With Follicular Lymphoma | ClinicalTrials.gov, accessed August 19, 2025, https://clinicaltrials.gov/study/NCT00475644
36. (PDF) Potential role of enzastaurin in the treatment of patients with relapsed or refractory advanced cutaneous T-cell lymphomas: a review - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/270132494_Potential_role_of_enzastaurin_in_the_treatment_of_patients_with_relapsed_or_refractory_advanced_cutaneous_T-cell_lymphomas_a_review
37. Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/27217449/
38. A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | Dana-Farber Cancer Institute, accessed August 19, 2025, https://www.dana-farber.org/clinical-trials/06-059
39. FDA Grants Fast Track Status for Enzastaurin - U.S. Pharmacist, accessed August 19, 2025, https://www.uspharmacist.com/article/fda-grants-fast-track-status-for-enzastaurin
40. Denovo Biopharma Pipeline, accessed August 19, 2025, https://mail.denovobiopharma.com/Pipeline.html
41. First Patient Dosed in Biomarker-Guided Phase 3 Study of DB102 (Enzastaurin) in Patients with Newly-Diagnosed Glioblastoma (GBM) - Denovo Biopharma, accessed August 19, 2025, https://www.denovobiopharma.com/en/news_info.html?id=116
42. Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ | ClinicalTrials.gov, accessed August 19, 2025, https://clinicaltrials.gov/study/NCT03263026
43. ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1 - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/32250167/
44. Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1 | Blood | American Society of Hematology, accessed August 19, 2025, https://ashpublications.org/blood/article/134/Supplement_1/5330/425223/Engine-Phase-III-Randomized-Study-of-Enzastaurin-R
45. Improved Survival with Enzastaurin Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients with the Novel Genetic Biomarker, DGM1 - Denovo Biopharma, accessed August 19, 2025, https://www.denovobiopharma.com/Publications/ASH_2018.pdf
46. ENGINE: Phase III randomized study of enzastaurin/R-CHOP versus placebo/R-CHOP in frontline high-risk diffuse large B-cell lymphoma patients with novel genomic biomarker DGM1. - ASCO Publications, accessed August 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.TPS7569
47. Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ - Mayo Clinic, accessed August 19, 2025, https://www.mayo.edu/research/clinical-trials/cls-20463114
48. Enzastaurin - Aytu BioPharma/ Denovo Biopharma - AdisInsight, accessed August 19, 2025, https://adisinsight.springer.com/drugs/800015989
49. Denovo Biopharma LLC's Phase 3 Pivotal ENGINE Study of DB102 (Enzastaurin) in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Is Fully Enrolled - PR Newswire, accessed August 19, 2025, https://www.prnewswire.com/news-releases/denovo-biopharma-llcs-phase-3-pivotal-engine-study-of-db102-enzastaurin-in-first-line-diffuse-large-b-cell-lymphoma-dlbcl-is-fully-enrolled-301171719.html
50. CTNI-08. DB102-01 ENGAGE STUDY: A BIOMARKER-GUIDED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE 3 CLINICAL TRIAL OF DB102 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/356349592_CTNI-08_DB102-01_ENGAGE_STUDY_A_BIOMARKER-GUIDED_RANDOMIZED_DOUBLE-BLIND_PLACEBO-CONTROLLED_MULTI-CENTER_PHASE_3_CLINICAL_TRIAL_OF_DB102_IN_PATIENTS_WITH_NEWLY_DIAGNOSED_GLIOBLASTOMA_GBM
51. Three DB102 (Enzastaurin) Presentations at ASCO and the 15th International Conference on Malignant Lymphoma (ICML) - FirstWord Pharma, accessed August 19, 2025, https://firstwordpharma.com/story/4792843
52. A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 | ClinicalTrials.gov, accessed August 19, 2025, https://clinicaltrials.gov/study/NCT03776071
53. Enzastaurin Dosed in First Phase 3 Study of Newly Diagnosed Glioblastoma Multiforme, accessed August 19, 2025, https://www.targetedonc.com/view/enzastaurin-dosed-in-first-phase-3-study-of-newly-diagnosed-glioblastoma-multiforme
54. Kinenza (enzastaurin) News - LARVOL Sigma, accessed August 19, 2025, https://sigma.larvol.com/product.php?e1=1516&tab=newstrac
55. Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome - The VEDS Movement, accessed August 19, 2025, https://thevedsmovement.org/2022/07/27/aytu-biopharma-announces-initiation-of-the-ar101-prevent-trial-for-the-treatment-of-vascular-ehlers-danlos-syndrome/
56. Enzastaurin Hydrochloride - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 19, 2025, https://synapse.patsnap.com/drug/f0fee2b51c3349ee8aaa766ba96d3021
57. A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE). - Orphanet, accessed August 19, 2025, https://www.orpha.net/en/research-trials/clinical-trial/628873?name=&mode=&country=&recruiting=0&terminated=0
58. Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome - The VEDS Movement, accessed August 19, 2025, https://thevedsmovement.org/2022/03/10/aytu-biopharma-announces-ar101-granted-orphan-designation-in-europe-for-the-treatment-of-ehlers-danlos-syndrome/
59. Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe, accessed August 19, 2025, https://www.ehlers-danlos.com/aytu-biopharma-announces-ar101-granted-orphan-designation-in-europe/
60. vEDS Clinical Trial - The Ehlers Danlos Society, accessed August 19, 2025, https://www.ehlers-danlos.com/veds-clinical-trial/
61. VEDS Clinical Trial - Enzastaurin - Annabelle's Challenge, accessed August 19, 2025, https://www.annabelleschallenge.org/veds-clinical-trial
62. Enzastaurin safety review: Data from phase I and phase II trials - ASCO Publications, accessed August 19, 2025, https://ascopubs.org/doi/10.1200/jco.2006.24.18_suppl.13077
63. Enzastaurin Granted Orphan Drug Status for Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) - Eli Lilly Investors, accessed August 19, 2025, https://investor.lilly.com/static-files/7e82d334-1291-44c6-8592-78b9228e7ba7
64. Designating an Orphan Product: Drugs and Biological Products - FDA, accessed August 19, 2025, https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products
65. Search Orphan Drug Designations and Approvals - FDA, accessed August 19, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=208505
66. Enzastaurin - Orphanet, accessed August 19, 2025, https://www.orpha.net/en/drug/substance/76236?name=&mode=pat®ion=&status=all
67. EU/3/05/343 - orphan designation for treatment of glioma | European ..., accessed August 19, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-343
68. Search Orphan Drug Designations and Approvals - FDA, accessed August 19, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=277209
69. Enzastaurin Granted Orphan Drug Status for Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) | Eli Lilly and Company, accessed August 19, 2025, https://investor.lilly.com/news-releases/news-release-details/enzastaurin-granted-orphan-drug-status-treatment-diffuse-large-b
70. EU/3/22/2582 - orphan designation for treatment of Ehlers-Danlos syndrome, accessed August 19, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2582
71. FDA Grants Fast Track Designation to Enzastaurin in Newly Diagnosed Glioblastoma, accessed August 19, 2025, https://www.targetedonc.com/view/fda-grants-fast-track-designation-to-enzasaruin-in-newly-diagnose-glioblastoma
72. Aytu BioPharma Announces FDA Clearance of Investigational New, accessed August 19, 2025, https://firstwordpharma.com/story/5461257